A review of dolasetron as management of nausea and vomiting in cancer patients

Abstract

Objective. To systematically review the literature about the pharmacology, pharmacokinetics, efficacy, dosing, and adverse effects of dolasetron, and to define its role in the management of chemotherapy-and radiation-induced nausea and vomiting.

Data Synthesis. A MedLine search was conducted using 5-HT3-receptor antagonists, antiemetics, chemotherapy toxicity, dolasetron, emesis, nausea, and vomiting as search terms. Reference lists and bibliographies of pertinent articles were also identified and reviewed. Both preclinical and clinical literature were reviewed and analyzed.

Data Synthesis. Dolasetron is a serotonin type 3 (5-HT3)-receptor antagonist with potent antiemetic effects in the management of nausea and vomiting. Following administration, dolasetron is rapidly converted to hydrodolasetron, which is believed to be responsible for the drug's antiemetic activity. Results of multiple studies have demonstrated the efficacy of this agent in the prevention of chemotherapy-induced emesis, including that induced by cisplatin. As a single agent, dolasetron produces a complete response rate (RR) in 44% to 57% of patients treated with cisplatin (≥70 mg/m2) and in 59% to 80% of patients treated with moderately emetogenic chemotherapy, such as cyclophosphamide, methotrexate, and fluorouracil (CMF) therapy. When combined with dexamethasone, the RRs are increased. Dolasetron is well tolerated, with headache (24%) and diarrhea (12%) the most commonly reported adverse effects. The efficacy and safety of dolasetron are comparable to those observed with other 5-HT3-receptor antagonists. According to four recently published clinical practice guidelines for use of antiemetics, dolasetron is an appropriate first-line option for the prevention of nausea and vomiting due to moderately to highly emetogenic chemotherapy. Further clinical trials will determine the optimal dose and the role of this highly effective antiemetic agent for other purposes, such as treatment of delayed emesis and emesis resulting from radiation therapy and high-dose chemotherapy followed by bone marrow transplantation.

Keywords

5-HT3-receptor antagonists antiemetics chemotherapy toxicity dolasetron emesis nausea vomiting

Get full access to this article

View all access options for this article.

References

Dimmitt DC

Choo YS

Martin LA

Arumugham T

Hahne WF

Weir SJ.

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1. Biopharm Drug Dispos. 1999;20:29-39.

Reith MK

Sproles GD

Cheng LK.

Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab Dispos. 1995;23:806-812.

Sanwald P

David M

Dow J.

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996;24:602-609.

Dimmitt DC

Cramer MB

Keung A

Arumugham T

Weir S.

Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects. Cancer Chemother Pharmacol. 1999;43:126-132.

Lippert C

Keung A

Arumugham T

Eller M

Hahne W

Weir S.

The effect of food on the bioavailability of dolasetron mesylate tablets. Biopharm Drug Dispos. 1998;19:17-19.

Dimmitt DC

Choo YS

Martin LA

Arumugham T

Hahne WF

Weir SJ.

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2. Biopharm Drug Dispos. 1999;20:41-48.

Keung AC

Landriault H

Lefebvre M

et al.

Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Biopharm Drug Dispos. 1997;18:361-369.

Dempsey E

Bourque S

Spenard J

Landriault H.

Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. J Clin Pharmacol. 1996;36:903-910.

Coppes MJ

Yanofsky R

Pritchard S

et al.

Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol. 1999;21:274-283.

10.

Stubbs K

Martin LA

Dimmitt DC

Pready N

Hahne WF.

Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. J Clin Pharmacol. 1997;37:926-936.

11.

Dimmitt DC

Shah AK

Arumugham T

et al.

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment. J Clin Pharmacol. 1998;38:798-806.

12.

Lippert CL

Dimmitt DC

Martin L

Cramer MB

Plezia P

Hahne WF.

Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy. Am J Therapeutics. 1999;6:129-135.

13.

Kris MG

Grunberg SM

Gralla RJ

et al.

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol. 1994;12:1045-1049.

14.

Conroy T

Cappelaere P

Fabbro M

et al.

Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol. 1994;17:97-102.

15.

Yielding A

Bertoli L

Eisenberg P

et al.

Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol. 1996;19:619-623.

16.

Harman GS

Omura GA

Ryan K

Hainsworth JD

Cramer MB

Hahne WF.

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol. 1996;38:323-328.

17.

Kasimis BS

Tapazoglou E

Schulman P

Stewart WH

Hahne WF

Cramer MB.

A double-blind, randomized study of two different dosage regimens of intravenous dolasetron in patients receiving high-dose cisplatin chemotherapy. Cancer Invest. 1997;15:304-310.

18.

Chevallier B

Cappelaere P

Splinter T

et al.

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer. 1997;5:22-30.

19.

Hesketh P

Navari R

Grote T

et al.

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-Induced Emesis Prevention Group. J Clin Oncol. 1996;14:2242-2249.

20.

Audhuy B

Cappelaere P

Martin M

et al.

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996;32A:807-813.

21.

Kris MG

Pendergrass KB

Navari RM

et al.

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997;15:2135-2138.

22.

Hesketh PJ

Gandara DR

Hesketh AM

et al.

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996;4:141-146.

23.

Lofters WS

Pater JL

Zee B

et al.

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997;15:2966-2973.

24.

Fauser AA

Duclos B

Chemaissani A

et al.

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer. 1996;32A:1523-1529

25.

Rubinstein EB

Gralla RJ

Hainsworth JD

et al.

Randomized, double-blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. Cancer. 1997;79:1216-1224.

26.

Grote TH

Pineda LF

Figlin RA

et al.

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group. Cancer J Sci Am. 1997;3:45-51.

27.

Fauser AA

Pizzocaro G

Schueller J

Khayat D

Wilkinson P.

A double blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer. 2000;8:49-54.

28.

Coppes MJ

Lau R

Ingram LC

et al.

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Med Pediatr Oncol. 1999;33:99-105.

29.

Fauser AA

Russ W

Bischoff M.

Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Support Care Cancer. 1997;5:219-222.

30.

Bey P

Wilkinson PM

Resbeut M

et al.

A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer. 1996;4:378-383.

31.

Whitmore JB

Kris MG

Hesketh PJ

et al.

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials. Support Care Cancer. 1998;6:473-478.

32.

Anzemet [package insert]. Kansas City, MO: Hoechst Marion Roussel; 1997.

33.

Benedict CR

Arbogast R

Martin L

Patton L

Morrill B

Hahne W.

Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996;28:53-59.

34.

Ettinger S

Huber S

Kris MG

et al.

NCCN antiemesis practice guidelines. Oncology. 1997;11:57-89.

35.

Gralla RJ

Osoba D

Kris MG

et al.

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.

36.

American Society of Health-System Pharmacists

. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm. 1999;56:729-764.

37.

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer

. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol. 1998;9:811-819.